Immunotherapy Advances for Epithelial Ovarian Cancer.
Immunotherapy Advances for Epithelial Ovarian Cancer.
复制标题
上皮性卵巢癌免疫治疗进展。
DOI：
10.3390/cancers12123733
复制
发表时间：
2020-12-11
期刊：
影响因子：
5.2
通讯作者：
Vlad AM
中科院分区：
文献类型：
--
作者：
Hartnett EG;Knight J;Radolec M;Buckanovich RJ;Edwards RP;Vlad AM
上皮性卵巢癌的总体五年生存率为44%，在过去二十年中仅略有改善。尽管最初对包括化疗和手术切除肿瘤在内的标准治疗有反应，但病变总是复发，患者最终死于化疗抵抗性疾病。为了改善诊断为卵巢癌的妇女的预后，需要新的治疗方式。其中一种方式是免疫疗法，旨在提高患者免疫系统识别和攻击肿瘤细胞的能力。我们进行了一项回顾性研究，以确定一些最有希望的免疫治疗上皮性卵巢癌。特别强调免疫肿瘤学临床试验。为了改善诊断为上皮性卵巢癌（EOC）的妇女的预后，需要新的治疗方式，EOC是最具侵袭性的妇科癌症类型。大多数卵巢肿瘤被免疫效应细胞浸润，这为增强现有或触发新的抗肿瘤免疫机制的靶向方法提供了基本原理。近年来，免疫肿瘤学领域取得了显著的进展，尽管单药免疫疗法在几种实体瘤中的效果尚未扩展到卵巢癌。挑战仍然是确定哪种治疗组合最适合这种疾病，哪些患者可能受益，并确定如何将免疫治疗纳入EOC的护理标准。我们在这里回顾了一些最有希望的EOC免疫疗法，并重点介绍了目前在临床试验中的免疫疗法。
The overall five-year survival rate in epithelial ovarian cancer is 44% and has only marginally improved in the past two decades. Despite an initial response to standard treatment consisting of chemotherapy and surgical removal of tumor, the lesions invariably recur, and patients ultimately die of chemotherapy resistant disease. New treatment modalities are needed in order to improve the prognosis of women diagnosed with ovarian cancer. One such modality is immunotherapy, which aims to boost the capacity of the patient’s immune system to recognize and attack the tumor cells. We performed a retrospective study to identify some of the most promising immune therapies for epithelial ovarian cancer. Special emphasis was given to immuno-oncology clinical trials. New treatment modalities are needed in order to improve the prognosis of women diagnosed with epithelial ovarian cancer (EOC), the most aggressive gynecologic cancer type. Most ovarian tumors are infiltrated by immune effector cells, providing the rationale for targeted approaches that boost the existing or trigger new anti-tumor immune mechanisms. The field of immuno-oncology has experienced remarkable progress in recent years, although the results seen with single agent immunotherapies in several categories of solid tumors have yet to extend to ovarian cancer. The challenge remains to determine what treatment combinations are most suitable for this disease and which patients are likely to benefit and to identify how immunotherapy should be incorporated into EOC standard of care. We review here some of the most promising immune therapies for EOC and focus on those currently tested in clinical trials.
登录
查看更多内容
Th17诱导自体树突状细胞疫苗接种可促进卵巢癌患者的抗原特异性细胞和体液免疫。
影响因子：
16.6
作者：
Block MS;Dietz AB;Gustafson MP;Kalli KR;Erskine CL;Youssef B;Vijay GV;Allred JB;Pavelko KD;Strausbauch MA;Lin Y;Grudem ME;Jatoi A;Klampe CM;Wahner-Hendrickson AE;Weroha SJ;Glaser GE;Kumar A;Langstraat CL;Solseth ML;Deeds MC;Knutson KL;Cannon MJ
通讯作者：
Cannon MJ
影响因子：
6.4
作者：
ANGELOPOULOU, K;DIAMANDIS, EP;BUNTING, PS
通讯作者：
BUNTING, PS
影响因子：
45.3
作者：
Berek, Jonathan;Taylor, Peyton;Nicodemus, Christopher F.
通讯作者：
Nicodemus, Christopher F.
影响因子：
4.7
作者：
Bagnoli, M;Canevari, S;Miotti, S
通讯作者：
Miotti, S
影响因子：
5.8
作者：
Budiu, Raluca A.;Mantia-Smaldone, Gina;Vlad, Anda M.
通讯作者：
Vlad, Anda M.